AACR 2026

LBPO.CL01 Late-Breaking Research: Clinical Research 1 PO.CL01.01 Biomarkers Predictive of Therapeutic Benefit 1 PO.CL01.02 Biomarkers Predictive of Therapeutic Benefit 2 PO.CL01.07 Liquid Biopsies: Circulating Nucleic Acids 1 PO.CL01.12 Spatial Proteomics and Transcriptomics 1 PO.CL01.15 Prognostic Biomarkers 1 PO.CL01.18 Early Detection Biomarkers 1 PO.CL01.22 Circulating Tumor Cells, Metastasis, and Dissemination… PO.CL06.02 Mechanistic Insights for Targeted Therapies in Pediatri… PO.CL07.03 Targeting DNA Repair, Cell Cycle, and Tumor Metabolism PO.CL11.02 Survivorship, Supportive Care, and Quality of Life in O… LBPO.CL02 Late-Breaking Research: Clinical Research 2 PO.CL01.03 Biomarkers Predictive of Therapeutic Benefit 3 PO.CL01.08 Liquid Biopsies: Circulating Nucleic Acids 2 PO.CL01.19 Early Detection Biomarkers 2 PO.CL04.01 Cancer and Aging: Implications for Outcomes PO.CL04.02 Community-Engaged Approaches to Equity Across the Cance… PO.CL05.05 Immunomodulatory Effects of Targeted Therapies PO.CL05.11 Redefining Targeted Therapy: Bispecific T-Cell Engagers… PO.CL07.01 Data-Driven Approaches to Precision Oncology PO.CL07.05 Targeted Antigen Therapies and Immunity PO.CL12.04 Molecular Imaging, Radiomics, and Theranostics PO.CL01.04 Biomarkers Predictive of Therapeutic Benefit 4 PO.CL01.09 Liquid Biopsies: Circulating Nucleic Acids 3 PO.CL01.13 Spatial Proteomics and Transcriptomics 2 PO.CL01.16 Prognostic Biomarkers 2 PO.CL01.20 Diagnostic Biomarkers 1 PO.CL01.23 Circulating Tumor Cells, Metastasis, and Dissemination… PO.CL05.01 Adoptive Cell Therapy 1 PO.CL05.03 Combination Immunotherapies PO.CL07.02 Molecular Targeted Therapy PO.CL12.01 Molecular Classification and Tumor Biology in Cancer PO.CL01.05 Biomarkers Predictive of Therapeutic Benefit 5 PO.CL01.10 Liquid Biopsies: Circulating Nucleic Acids 4 PO.CL01.17 Prognostic Biomarkers 3 PO.CL05.02 Adoptive Cell Therapy 2 PO.CL05.12 Redefining Targeted Therapy: Bispecific T-Cell Engagers… PO.CL08.02 Effects of Ionizing Radiation on Normal Tissues and FLA… PO.CL09.01 Precision Oncology and Real World Data PO.CL09.03 Retrospective Observational Studies PO.CL11.01 Biological and Clinical Consequences of Cancer Therapy PO.CL12.03 Epigenetics, Cytogenetics, and Clinical Molecular Genet… LBPO.CL03 Late-Breaking Research: Clinical Research 3 PO.CL01.14 Spatial Proteomics and Transcriptomics 3 PO.CL01.21 Diagnostic Biomarkers 2 PO.CL02.01 Biostatistics in Clinical Trials / Surgical Oncology PO.CL05.04 Immune Checkpoint Blockade PO.CL05.06 Clinical Correlates of Immunotherapy PO.CL05.09 Inflammation, Immunity, and Cancer PO.CL05.13 Vaccines and Other Immunomodulatory Agents PO.CL07.04 Combination Targeted Therapy PO.CL08.01 Radiation and Photodynamic Therapy Response Modifiers PO.CL09.02 Real World Data to Provide Real World Evidence LBPO.CL04 Late-Breaking Research: Clinical Research 4 PO.CL01.06 Biomarkers Predictive of Therapeutic Benefit 6 PO.CL01.11 Liquid Biopsies: Circulating Nucleic Acids 5 PO.CL05.07 Immune Response to Therapies PO.CL05.08 Immunomodulatory Agents and Interventions PO.CL05.10 Tumor Microenvironment Modulators PO.CL06.01 Immunotherapies in Pediatric Cancers PO.CL06.03 Targeted Therapies, Predispositions, and Survivorship i… PO.CL09.04 Real World Impact of Prognostic and Predictive Paramete… PO.CL12.02 Translational Biomarkers and Emerging Molecular Approac…

LBPO.ET01 Late-Breaking Research: Experimental and Molecular Ther… PO.ET01.02 Mechanism-Guided Development of Targeted Cancer Therapi… PO.ET01.04 Kinase and Signaling Pathway Dependencies Driving Cance… PO.ET02.07 Innovative Therapeutic Modalities and Translational Pla… PO.ET02.09 RNA, Gene and Cell Therapies, and Enabling Assay Techno… PO.ET02.11 Novel Therapeutics and Drug Targets 1 PO.ET03.01 Mechanisms of Drug Resistance 1 PO.ET04.01 Gene and Vector-Based Therapy PO.ET06.02 DNA Damage and Repair 1 PO.ET09.06 Novel Antitumor Agents 1 PO.ET01.01 Engineering the Next Wave of Antibody-Based Cancer Ther… PO.ET02.01 Antibody-Drug Conjugates and Linker Engineering 1 PO.ET02.02 Antibody-Drug Conjugates and Linker Engineering 2 PO.ET02.05 Antibody Technologies and Platforms 1 PO.ET03.02 Mechanisms of Drug Resistance 2 PO.ET03.07 Targeting Drug Resistance 1: Apoptosis and Autophagy PO.ET03.08 Targeting Drug Resistance 2: RAS Signaling PO.ET06.03 DNA Damage and Repair 2 PO.ET07.01 Quantitative Pharmacology and Translational Modeling LBPO.ET02 Late-Breaking Research: Experimental and Molecular Ther… PO.ET01.06 Targeting Cell Surface Vulnerabilities to Overcome Ther… PO.ET02.08 Nanocarriers and Drug Delivery Systems PO.ET02.12 Novel Therapeutics and Drug Targets 2 PO.ET03.04 Overcoming Chemotherapy Resistance PO.ET03.06 Drug Resistance 1: Antibodies and ADCs PO.ET05.02 Cellular Responses to Anticancer Drugs PO.ET06.04 Molecular Targets 1 PO.ET07.02 Pharmacogenomics and Translational Biomarkers for Preci… PO.ET09.09 Novel Targets and Pathways PO.ET01.03 Next-Generation Targeted Therapies Directed Against Tum… PO.ET02.03 Antibody-Drug Conjugates and Linker Engineering 3 PO.ET02.06 Antibody Technologies and Platforms 2 PO.ET02.10 Drug Combinations, Repurposing, and Differentiation PO.ET02.13 Hematologic Malignancies and Novel Therapeutic Modaliti… PO.ET08.01 Strategies to Enhance the Therapeutic Index of Radiothe… PO.ET09.01 Epigenetic Modulators 1 PO.ET09.03 Proximity-Induced Drug Discovery 1 PO.ET09.07 Novel Antitumor Agents 2 LBPO.ET03 Late-Breaking Research: Experimental and Molecular Ther… PO.ET02.04 Antibody-Drug Conjugates and Linker Engineering 4 PO.ET02.14 Tumor Microenvironment, Multispecifics, and Immunomodul… PO.ET05.01 Mechanisms of Anticancer Drug Action PO.ET06.01 Cell Death Pathways and Treatment PO.ET06.05 Molecular Targets 2 PO.ET08.02 Radiopharmacuetical Platforms for Theranostic Precision… PO.ET09.04 Proximity-Induced Drug Discovery 2 PO.ET09.05 Multi-Axis Antineoplastic Agents PO.ET09.10 Tyrosine Kinase, Phosphatase, and Other Inhibitors LBPO.ET04 Late-Breaking Research: Experimental and Molecular Ther… PO.ET01.05 Overcoming Microenvironmental and Delivery Barriers in… PO.ET03.03 Novel Strategies to Reverse Drug Resistance PO.ET03.05 Drug Resistance 2: Tyrosine Kinase Inhibitors PO.ET05.03 Role of the Microenvironment in Therapeutic Response PO.ET06.06 Tumor Diagnostics, Prognostics, and Therapeutic Outcomes PO.ET08.03 Targeted Radiopharmaceuticals and Combination Strategie… PO.ET09.02 Epigenetic Modulators 2 PO.ET09.08 Novel Antitumor Agents 3

PO.TB02.02 Molecular Pathology PO.TB04.01 Ex Vivo Systems: Patient-Derived, Patient-Specific Tumo… PO.TB04.05 Noninvasive Imaging and Analysis of Animal and Tissue M… PO.TB05.01 Developmental Origins, Drivers, and Heterogeneity in Pe… PO.TB07.01 Stem Cell Plasticity and Lineage Reprogramming in Cancer PO.TB09.03 Methods to Measure Tumor Evolution and Heterogeneity PO.TB10.06 Spatial Protein Profiling and Multi-Modal Mapping of Tu… PO.TB10.12 Physicochemical Modulation of Cancer Ecosystems: Mechan… PO.TB02.01 In Vivo Imaging PO.TB03.01 Therapies Targeting Metastasis PO.TB03.04 Characterization of Metastases by Imaging and Profiling PO.TB04.06 In Vivo Models 1: Mouse, Zebrafish, and Alternative Spe… PO.TB07.02 Metabolic and Transcriptional Control of Cancer Stem Ce… PO.TB10.01 Tumorigenesis and Early Microenvironmental Trajectories PO.TB10.05 Aging and Host Determinants of Tumor Progression: The M… PO.TB10.10 Tertiary Lymphoid Structures in Cancer LBPO.TB01 Late-Breaking Research: Tumor Biology 1 PO.TB03.05 Migration and Invasion PO.TB04.02 Humanized Mouse Models PO.TB04.07 In Vitro Models 1: 2D and 3D PO.TB05.03 Pediatric Cancer Genomics and Epigenomics PO.TB09.02 Tumor Evolution PO.TB10.03 Microenvironmental Determinants of Therapy Response and… PO.TB10.15 Extracellular Vesicles and Long-Range Tumor-Host Commun… PO.TB10.17 Therapeutic Modulation of the Tumor Microenvironment: N… LBPO.TB02 Late-Breaking Research: Tumor Biology 2 PO.TB01.01 Angiogenesis PO.TB03.02 Epithelial-to-Mesenchymal Transition PO.TB04.03 In Vitro Models 2: 2D, 3D, Organoids, and Spheroids PO.TB07.03 Contextual Determinants of Cancer Stemness and Tumor Ag… PO.TB10.08 Spatial Niches and Functional Boundaries within the Tum… PO.TB10.14 Microbiome-Tumor-Immune Crosstalk PO.TB10.18 Novel Experimental Platforms and Causal Inference PO.TB10.19 Tumor-Immune Crosstalk PO.TB03.03 Mechanisms of Metastasis PO.TB03.06 Metastatic Niches and Microenvironment PO.TB04.04 In Vivo Models 2: Genetically Engineered Mouse Models,… PO.TB05.02 Pediatric Cancer Models PO.TB10.02 Metastasis and Organ-Specific Microenvironmental Evolut… PO.TB10.07 Spatial Niches and Functional Boundaries within the Tum… PO.TB10.11 Fibroblasts as Architects of the Tumor Microenvironment PO.TB10.13 Tumor-Neuron Interactions and Neuro-Regulation of Cancer LBPO.TB03 Late-Breaking Research: Tumor Biology 3 PO.TB04.08 Tumor Models and Assays: In Vitro, In Vivo PO.TB06.01 Biological Mechanisms of Tumor and Normal Tissue Respon… PO.TB08.01 Tumor Adhesion PO.TB09.01 Tumor Heterogeneity PO.TB10.04 Microenvironmental Determinants of Therapy Response and… PO.TB10.09 Functional and Spatial Regulation of Immune Evasion and… PO.TB10.16 Therapeutic Modulation of the Tumor Microenvironment: N…

LBPO.MCB01 Late-Breaking Research: Molecular/Cellular Biology and… PO.MCB02.02 Targeting Mitochondria and Metabolic Vulnerabilities fo… PO.MCB03.03 Tumor Cell Plasticity, Microenvironment, and Stress-Res… PO.MCB05.02 Mechanisms and Targets in DNA Damage Repair PO.MCB08.01 Genomic Dissection to Define Novel Therapeutic Strategi… PO.MCB09.03 Metabolite Control of Chromatin, Redox, and Cellular St… PO.MCB11.01 Tumor Suppressors PO.MCB01.01 Cell Cycle PO.MCB06.01 Chromatin Structure and Function PO.MCB06.02 DNA Methylation PO.MCB08.02 Genomic Drivers of Cancer Pathogenesis PO.MCB09.01 Metabolic Regulation in Breast and Gynecologic Cancers PO.MCB10.01 MicroRNAs as Cancer Biomarkers, Therapeutic Targets, an… PO.MCB03.02 RTK-ERBB-PI3K and New Targets in Therapeutic Resistance PO.MCB06.03 Epigenetic Changes as Molecular Markers of Cancer PO.MCB06.04 Epigenomics PO.MCB08.03 Genomic Profiling to Understand Cancer Biology PO.MCB09.04 Metabolic Studies in Brain, Pediatric, and Hematologic… PO.MCB11.02 Tumorigenesis Drivers LBPO.MCB02 Late-Breaking Research: Molecular/Cellular Biology and… PO.MCB02.01 Cell Death Regulation and Therapeutic Resistance in Can… PO.MCB05.01 Insights into Genomic Instability PO.MCB07.01 Oncogenic Transcription Factors and Cancer Programs PO.MCB09.05 Metabolic Features of Thoracic and Urologic Cancers PO.MCB09.06 Metabolic Alterations in Colorectal and Gastrointestina… PO.MCB03.01 RAS/MAPK Signaling, KRAS Targeting, and Adaptive Resist… PO.MCB04.02 Senescence and Cell Stress PO.MCB07.03 Mechanisms and Dynamics of Gene Expression PO.MCB08.04 Genetic and Transcriptomic Dissection of Cancer Evoluti… PO.MCB10.02 Functional Roles of Noncoding RNAs in Cancer Progressio… PO.MCB04.01 Hypoxic and Proteotoxic Stress Response PO.MCB07.02 Chromatin Architecture and Regulatory Landscapes PO.MCB07.04 Transcription Factor Function in Cell Identity, Signali… PO.MCB08.05 Genomic Approaches to Define Tumor Biology and Clinical… PO.MCB09.02 Metabolic Vulnerabilities in Pancreatic, Hepatic, and R…

LBPO.IM01 Late-Breaking Research: Immunology 1 PO.IM01.01 Immune Cell Biology and Tumor-Immune Crosstalk PO.IM01.07 Alternative Cell Type and in Situ Cell Therapies PO.IM02.01 Inflammation and Cancer Progression PO.IM03.01 Virology and Cancer LBPO.IM02 Late-Breaking Research: Immunology 2 PO.IM01.05 CAR T Cell Targets and TME Reprogramming PO.IM01.10 Combination Immunotherapies PO.IM01.16 T Cell Engagers 1 PO.IM02.02 Innate Immunity in Cancer PO.IM01.02 Modifiers of Inflammation and the Tumor Microenvironment PO.IM01.04 Immune Mechanisms Invoked by Other Therapies and Exposu… PO.IM01.11 Immune Checkpoints PO.IM02.03 Microbiome, Inflammation, and Response to Immunotherapy… LBPO.IM03 Late-Breaking Research: Immunology 3 PO.IM01.03 Vaccine Platforms and Target Identification PO.IM01.06 CAR T Cell Functional Enhancement PO.IM01.12 Immunomodulatory Agents PO.IM01.15 Monoclonal Antibodies and Antibody-Cytokine Platforms PO.IM02.04 Adaptive Immunity in Cancer PO.IM01.08 TCR and Autologous T Cell Therapies PO.IM01.09 T Cell Engagers 2 / Antibody-Drug Conjugates 1 PO.IM01.14 Bi- and Tri-Specific Antibody Therapies PO.IM02.06 Oncogenic Pathways and Cancer Immunity PO.IM01.13 Antibody-Drug Conjugates 2 PO.IM01.17 High-Dimensional Immune Profiling and Preclinical Model… PO.IM02.05 Tumor-induced Immune Suppression PO.IM02.07 Novel Models of Immunotherapy Response

PO.BCS01.01 Application of Bioinformatics to Cancer Biology 1 PO.BCS01.06 Digital Pathology 1 PO.BCS01.11 Liquid Biopsy: Multi-Analyte and Multi-Omic PO.BCS02.01 Agentic AI in Cancer LBPO.BCS01 Late-Breaking Research: Bioinformatics, Computational B… PO.BCS01.02 Application of Bioinformatics to Cancer Biology 2 PO.BCS01.07 Digital Pathology 2 PO.BCS01.09 Integrative Computational Approaches 1 PO.BCS01.15 Sequence Analysis PO.BCS01.03 Application of Bioinformatics to Cancer Biology 3 PO.BCS01.16 Integration of Clinical and Research Data PO.BCS02.02 Large Language Models in the Clinic PO.BCS02.04 Radiomics and AI in Medical Imaging PO.BCS01.04 Application of Bioinformatics to Cancer Biology 4 PO.BCS01.08 Digital Pathology 3 PO.BCS01.10 Integrative Computational Approaches 2 PO.BCS02.06 Machine Learning Approaches for Cancer Prediction PO.BCS01.05 Application of Bioinformatics to Cancer Biology 5 PO.BCS01.12 New Software Tools for Data Analysis PO.BCS02.03 Machine Learning for Image Analysis PO.BCS02.05 Deep Learning in Cancer LBPO.BCS02 Late-Breaking Research: Bioinformatics, Computational B… PO.BCS01.13 New Algorithms and Computational Methods PO.BCS01.14 Network Biology and Precision Medicine PO.BCS01.17 Mathematical Modeling and Statistical Methods

PO.PS01.04 Survivorship Research Addressing Cancer Disparities PO.PS01.10 Survivorship Research PO.PS01.01 Biomarkers of Endogenous or Exogenous Exposures, Early… PO.PS01.05 Epidemiology: Cancer Incidence, Mortality, Patterns, an… PO.PS01.02 Cancer Surveillance: Emerging Cancer Trends and Populat… PO.PS01.07 Genetic Epidemiology 1: GxE, GWAS, Polygenic Risk Score… PO.PS01.03 Etiology and Molecular Epidemiology Approaches to Decip… PO.PS01.06 Diet, Alcohol, and Tobacco, and Other Lifestyle Factors LBPO.PS01 Late-Breaking Research: Population Sciences PO.PS01.08 Genetic Epidemiology 2: Pathway Analysis, Sequencing, F… PO.PS01.12 Environmental and Occupational Risk Factors, Infection,… PO.PS01.09 Risk Prediction Modeling, Screening, Early Detection, a… PO.PS01.11 Psychosocial and Behavioral Epidemiology, Health Servic…

LBPO.CH01 Late-Breaking Research: Chemistry PO.CH01.07 Computational, Technological, and Mechanistic Advances PO.CH01.06 Antibodies, Antibody-Drug Conjugates, and Nucleic Acids PO.CH03.01 Structural and Chemical Biology PO.CH01.05 Natural Products PO.CH01.01 Targeted Protein Degradation and Induced Proximity PO.CH01.03 New Ligands and Inhibitors PO.CH01.02 Screening and Technology Advances for Probe and Drug Di… PO.CH01.04 Drug Delivery PO.CH02.01 Proteomics: Biomarker Discovery and Signaling Networks PO.CH02.02 Multi-Omics, Systems Biology, and Biological Mass Spect…

PO.PR02.01 Experimental Chemoprevention and Interception: Data and… PO.PR02.03 Cancer in the Community: Epidemiology, Experimental Kno… PO.PR01.01 Cancer Disparities LBPO.PR01 Late-Breaking Research: Prevention, Early Detection, an… PO.PR01.04 Metabolism and Microbiome in Cancer Initiation and Prev… PO.PR01.02 Early Detection and Interception PO.PR01.03 Genomics, Proteomics, Biomarkers, and Risk Stratificati… PO.PR01.05 Advances in Survivorship PO.PR02.02 Cancer and Cancer Related Alterations, Detection Approa…

PO.CT01.02 First-in-Human Phase I Clinical Trials PO.CT01.01 Phase 0 and First-in-Human Phase I Clinical Trials PO.CT01.05 Phase II and Phase III Clinical Trials PO.CT01.03 Phase I Clinical Trials PO.CT01.04 Phase II Clinical Trials

PO.CTP01.01 Phase I Clinical Trials in Progress PO.CTP01.03 Phase II and Phase III Clinical Trials in Progress PO.CTP01.02 Phase I and Phase II Clinical Trials in Progress

PO.SHP01.01 Science and Health Policy 1 PO.SHP01.02 Science and Health Policy 2

PO.ADV01 Advocates Poster Session 1 PO.ADV02 Advocates Poster Session 2

PO.EN01.01 Hormone Receptor Signaling and Therapeutic Targeting PO.EN01.02 Signaling Pathways, Metabolism, and Emerging Therapeuti…

PO.MD01.01 AACR Project GENIE: Predictive Models and AI PO.MD01.02 AACR Project GENIE: Genomic Characterization

PO.RSP01.01 Regulatory Science and Policy

PO.SCIED01 2026 AACR Undergraduate Scholars and Margaret Foti Unde…